Asset
AVALOTCAGENE ONTAPARVOVEC
Ultragenyx Pharmaceutical Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05345171 | phase3 | active_not_recruiting | 2022-10-18 | 2027-09-01 | Ultragenyx Pharmaceutical Inc | Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency |
FDA applications (0)
This company has no applications containing this asset.